Abstract

To investigate mechanisms by which thymoquinone (TQ) can prevent methotrexate- (MTX-) induced hepatorenal toxicity, TQ (10 mg/kg) was administered orally for 10 days. In independent rat groups, MTX hepatorenal toxicity was induced via 20 mg/kg i.p. at the end of day 3 of experiment, with or without TQ. MTX caused deterioration in kidney and liver function, namely, blood urea nitrogen, creatinine, alanine aminotransferase, and aspartate aminotransferase. MTX also caused distortion in renal and hepatic histology, with significant oxidative stress, manifested by decrease in reduced glutathione and catalase, as well as increase in malondialdehyde levels. In addition, MTX caused nitrosative stress manifested by increased nitric oxide, with upregulation of inducible nitric oxide synthase. Furthermore, MTX caused hepatorenal inflammatory effects as shown by increased tumor necrosis factor-α, besides upregulation of necrosis factor-κB and cyclooxygenase-2 expressions. MTX also caused apoptotic effect, as it upregulated caspase 3 in liver and kidney. Using TQ concurrently with MTX restored kidney and liver functions, as well as their normal histology. TQ also reversed oxidative and nitrosative stress, as well as inflammatory and apoptotic signs caused by MTX alone. Thus, TQ may be beneficial adjuvant that confers hepatorenal protection to MTX toxicity via antioxidant, antinitrosative, anti-inflammatory, and antiapoptotic mechanisms.

Highlights

  • Methotrexate (MTX) is one of the most widely used anticancer drugs

  • The ready to use inducible nitric oxide synthase, nuclear factor- (NF-)κB/p65, COX-2, and caspase 3 rabbit polyclonal antibodies were purchased from Thermo Fisher Scientific Inc./Lab Vision (CA, USA)

  • It was noticed that the improvement of the kidney function was more pronounced than that of the liver function, as the former was reversed to levels not statistically significant from control

Read more

Summary

Introduction

Methotrexate (MTX) is one of the most widely used anticancer drugs. Cytotoxic effects of MTX may affect tumor cells, and extend to affect vital organs. One of the most prominent toxicities caused by MTX chemotherapy is nephrotoxicity [1, 2]. MTX-induced renal dysfunction is initiated by the precipitation of MTX and its metabolites in the renal tubules. The elevated toxic levels of MTX contribute to multiple vital organ damage, including the liver. The prevalence of MTX-induced liver fibrosis and cirrhosis in patients may reach up to 50% and 26%, respectively [4]. Finding an adjuvant hepatorenal protective compound is, mandatory for the safe use of this indispensable anticancer immunosuppressant drug

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call